ReviewFrontiers in immunology2026
IgA nephropathy: a novel pathway in immunopathogenesis dependent on the timing of Epstein-Barr virus infection.
Review in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
IgA nephropathy (IgAN) is an autoimmune disease in which polymeric IgA1, with joining (J) chain and altered glycosylation of the hinge region (HR), acts as an autoantigen recognized by naturally occurring IgG antibodies, resulting in generation of nephritogenic immune complexes (IC) that deposit in the kidney mesangium. By these criteria, IgA in IC and mesangial deposits displays properties identical to those of IgA produced by plasma cells infected by Epstein-Barr virus (EBV). Although ~95% of adults worldwide are EBV infected, there are important differences in the timing of infection in countries and areas with marked dissimilarities in socio-economic conditions. Epidemiological data convincingly documented that early EBV infection in children who live in developing countries, or in economically disadvantaged areas, display a significantly reduced frequency of IgAN compared to individuals from economically developed countries in which IgAN has been recognized as the leading cause of glomerulonephritis. Because physiological maturation of the IgA system is normally delayed until adolescence, in young children EBV infects B cells of Ig isotypes other than IgA, as these are relatively sparse. This early infection induces EBV-specific immune responses that prevent later infection of IgA-producing cells at older ages when these cells are more plentiful.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.